Type 3 Deiodinase: Role in Cancer Growth, Stemness, and Metabolism

Deiodinases are selenoenzymes that catalyze thyroid hormones (THs) activation (type 1 and type 2, D1 and D2, respectively) or inactivation (type 3, D3). THs are essential for proper body development and cellular differentiation. Their intra- and extra-cellular concentrations are tightly regulated by deiodinases with a pre-receptorial control thus generating active or inactive form of THs. Changes in deiodinases expression are anatomically and temporally regulated and influence the downstream TH signaling. D3 overexpression is a feature of proliferative tissues such as embryo or cancer tissues. The enhanced TH degradation by D3 induces a local hypothyroidism, thus inhibiting THs transcriptional activity. Of note, overexpression of D3 is a feature of several highly proliferative cancers. In this paper, we review recent advances in the role of D3 in cancer growth, stemness, and metabolic phenotype. In particular, we focus on the main signaling pathways that result in the overexpression of D3 in cancer cells and are known to be relevant to cancer development, progression, and recurrence. We also discuss the potential role of D3 in cancer stem cells metabolic phenotype, an emerging topic in cancer research.

[1]  N. Itano Metabolic reprogramming of cancer stem cells by hyaluronan production , 2015 .

[2]  M. Todaro,et al.  Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment , 2014, Cell Death and Disease.

[3]  C. Missero,et al.  The sonic hedgehog-induced type 3 deiodinase facilitates tumorigenesis of basal cell carcinoma by reducing Gli2 inactivation. , 2014, Endocrinology.

[4]  Gang Huang,et al.  HSP40 Interacts with Pyruvate Kinase M2 and Regulates Glycolysis and Cell Proliferation in Tumor Cells , 2014, PloS one.

[5]  P. Larsen,et al.  The deiodinases and the control of intracellular thyroid hormone signaling during cellular differentiation , 2013, Biochimica et biophysica acta.

[6]  E. Cuyás,et al.  The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells , 2013, Cell cycle.

[7]  Jun Yao,et al.  Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. , 2013, Cancer cell.

[8]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[9]  C. Pecqueur,et al.  Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells , 2013, International journal of cell biology.

[10]  P. Larsen,et al.  β-Catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. , 2012, Gastroenterology.

[11]  S. Wajner,et al.  Increased type 3 deiodinase expression in papillary thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[12]  P. Naveilhan,et al.  Comparison of Spheroids Formed by Rat Glioma Stem Cells and Neural Stem Cells Reveals Differences in Glucose Metabolism and Promising Therapeutic Applications* , 2012, The Journal of Biological Chemistry.

[13]  J. Bixby,et al.  Neuronal Hypoxia Induces Hsp40-Mediated Nuclear Import of Type 3 Deiodinase As an Adaptive Mechanism to Reduce Cellular Metabolism , 2012, The Journal of Neuroscience.

[14]  A. Bianco,et al.  Thyroid Hormone Deiodinases and Cancer , 2012, Front. Endocrin..

[15]  P. Vigneri,et al.  Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells , 2012 .

[16]  G. Blatch,et al.  Human DNAJ in cancer and stem cells. , 2011, Cancer letters.

[17]  V. Ramanujan,et al.  Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. , 2011, Biochemical and biophysical research communications.

[18]  M. Plateroti,et al.  The thyroid hormones and their nuclear receptors in the gut: from developmental biology to cancer. , 2011, Biochimica et biophysica acta.

[19]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[20]  M. Keating,et al.  Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells , 2011, The Journal of Biological Chemistry.

[21]  M. Wachs,et al.  Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  Yang Liu,et al.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.

[23]  M. Dentice Hedgehog-mediated regulation of thyroid hormone action through iodothyronine deiodinases , 2011, Expert opinion on therapeutic targets.

[24]  M. Dentice,et al.  Role of type 3 deiodinase in cancer , 2009, Expert opinion on therapeutic targets.

[25]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[26]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[27]  G. Tell,et al.  ΔNp73α inhibits PTEN expression in thyroid cancer cells , 2009, International journal of cancer.

[28]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[29]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[30]  J. Harney,et al.  Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. , 2008, The Journal of clinical investigation.

[31]  A. Bianco,et al.  Reawakened interest in type III iodothyronine deiodinase in critical illness and injury , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[32]  A. Bianco,et al.  Activation and inactivation of thyroid hormone by deiodinases: Local action with general consequences , 2008, Cellular and Molecular Life Sciences.

[33]  A. Bianco,et al.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. , 2008, Endocrine reviews.

[34]  F. Frasca,et al.  TAp73α Increases p53 Tumor Suppressor Activity in Thyroid Cancer Cells via the Inhibition of Mdm2-Mediated Degradation , 2008, Molecular Cancer Research.

[35]  P. Larsen,et al.  Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes , 2007, Proceedings of the National Academy of Sciences.

[36]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[37]  F. Frasca,et al.  p53 family proteins in thyroid cancer. , 2007, Endocrine-related cancer.

[38]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[39]  R. Versteeg,et al.  Regulation of type III iodothyronine deiodinase expression in human cell lines. , 2006, Endocrinology.

[40]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.

[41]  P. Yen,et al.  Thyroid hormone action at the cellular, genomic and target gene levels , 2006, Molecular and Cellular Endocrinology.

[42]  T. Shimokawa,et al.  Inhibition of GLI1 gene activation by Patched1. , 2006, The Biochemical journal.

[43]  S. Fiering,et al.  Type 3 deiodinase is critical for the maturation and function of the thyroid axis. , 2006, The Journal of clinical investigation.

[44]  P. Jackson,et al.  Dual degradation signals control Gli protein stability and tumor formation. , 2006, Genes & development.

[45]  E. Mazzon,et al.  The p53-homologue p63 may promote thyroid cancer progression. , 2005, Endocrine-related cancer.

[46]  Stephen A. Huang,et al.  Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. , 2005, Thyroid : official journal of the American Thyroid Association.

[47]  A. Joyner,et al.  In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog , 2005, Nature.

[48]  L. Rubin,et al.  Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. , 2005, The Journal of investigative dermatology.

[49]  Stephen A. Huang Physiology and pathophysiology of type 3 deiodinase in humans. , 2005, Thyroid : official journal of the American Thyroid Association.

[50]  A. Bianco,et al.  Adaptive Activation of Thyroid Hormone and Energy Expenditure , 2005, Bioscience reports.

[51]  P. Vaupel,et al.  Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.

[52]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[53]  M. Kempers,et al.  Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. , 2003, The Journal of clinical endocrinology and metabolism.

[54]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[55]  G. Van den Berghe,et al.  Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. , 2003, The Journal of clinical endocrinology and metabolism.

[56]  P. Larsen,et al.  Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. , 2003, The Journal of clinical endocrinology and metabolism.

[57]  J. Harney,et al.  Human Type 3 Iodothyronine Selenodeiodinase Is Located in the Plasma Membrane and Undergoes Rapid Internalization to Endosomes* , 2003, The Journal of Biological Chemistry.

[58]  P. Sánchez,et al.  Gli and hedgehog in cancer: tumours, embryos and stem cells , 2002, Nature Reviews Cancer.

[59]  C. Heldin,et al.  Smad regulation in TGF-beta signal transduction. , 2001, Journal of cell science.

[60]  P. Ingham,et al.  Hedgehog signaling in animal development: paradigms and principles. , 2001, Genes & development.

[61]  J. Taipale,et al.  The Hedgehog and Wnt signalling pathways in cancer , 2001, Nature.

[62]  P. Ingham,et al.  Mutations in the Sterol Sensing Domain of Patched suggest a Role for Vesicular Trafficking in Smoothened Regulation , 2001, Current Biology.

[63]  D. Baker,et al.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation , 2001, Nature Immunology.

[64]  A. Butte,et al.  Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. , 2000, The New England journal of medicine.

[65]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[66]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[67]  Q. Gu,et al.  Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.

[68]  R. Nusse,et al.  Wnt signaling: a common theme in animal development. , 1997, Genes & development.

[69]  M. Scott,et al.  Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.

[70]  J. Wong,et al.  Tadpole competence and tissue‐specific temporal regulation of amphibian metamorphosis: Roles of thyroid hormone and its receptors , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[71]  M. Obregon,et al.  Presence of growth factors-induced type III iodothyronine 5-deiodinase in cultured rat brown adipocytes. , 1995, Endocrinology.

[72]  S. Cheng,et al.  An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate. , 1991, Biochemistry.

[73]  M. Pierre,et al.  Induction of 5‐Deiodinase Activity in Astroglial Cells by 12‐O‐Tetradecanoylphorbol 13‐Acetate and Fibroblast Growth Factors , 1991, Journal of neurochemistry.

[74]  D. Fisher Management of Congenital Hypothyroidism , 1991 .

[75]  S. Cheng,et al.  Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Dussault,et al.  Effects of neonatal hyperthyroidism on the development of the hypothalamic-pituitary-thyroid axis in the rat. , 1982, Endocrinology.

[77]  P. Vigneri,et al.  Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. , 2012, International journal of cancer.

[78]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[79]  S. Pallud,et al.  Regulation of type 3 iodothyronine deiodinase expression in cultured rat astrocytes: role of the Erk cascade. , 1999, Endocrinology.

[80]  D. Fisher Clinical review 19: Management of congenital hypothyroidism. , 1991, The Journal of clinical endocrinology and metabolism.

[81]  T. Foley,et al.  Management of congenital hypothyroidism. , 1979, Pennsylvania medicine.

[82]  V. Galton,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Expression Profiles of the Three Iodothyronine , 2022 .